Literature DB >> 20826007

Differential responses of human microglia and blood-derived myeloid cells to FTY720.

Bryce A Durafourt1, Caroline Lambert, Trina A Johnson, Manon Blain, Amit Bar-Or, Jack P Antel.   

Abstract

Human microglia, monocyte-derived dendritic cells (DCs) and macrophages ex vivo express relatively higher levels of sphingosine-1-phosphate (S1P) receptor 1 (S1P1) mRNA as compared to other receptor subtypes. The S1P agonist FTY720 decreased ERK phosphorylation and induced myosin light chain (MLC) II phosphorylation only in macrophages and DCs. FTY720 inhibited IL-12p70 production (CD40L induced) by DCs and macrophages but not microglia (poly I:C induced). IL-10 production was increased in DCs and unaffected in other myeloid cells. Despite similar receptor expression patterns, the distinct myeloid cell populations present in the human CNS, under steady-state or inflammatory conditions, exhibit differential responses to FTY720.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20826007     DOI： 10.1016/j.jneuroim.2010.08.006

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  32 in total

1.  Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.

Authors:  Takashi Yoshino; Hiroko Tabunoki; Shigeo Sugiyama; Keitaro Ishii; Seung U Kim; Jun-Ichi Satoh
Journal:  Cell Mol Neurobiol       Date:  2011-04-26       Impact factor: 5.046

Review 2.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 3.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

4.  Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.

Authors:  Jerold Chun; Yasuyuki Kihara; Deepa Jonnalagadda; Victoria A Blaho
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

Review 5.  Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.

Authors:  Matthias Mehling; Ludwig Kappos; Tobias Derfuss
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

6.  Immune cell trafficking from the brain maintains CNS immune tolerance.

Authors:  Mohammad G Mohammad; Vicky W W Tsai; Marc J Ruitenberg; Masoud Hassanpour; Hui Li; Prue H Hart; Samuel N Breit; Paul E Sawchenko; David A Brown
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

Review 7.  Therapies for multiple sclerosis: considerations in the pediatric patient.

Authors:  Brenda Banwell; Amit Bar-Or; Gavin Giovannoni; Russell C Dale; Marc Tardieu
Journal:  Nat Rev Neurol       Date:  2011-01-11       Impact factor: 42.937

8.  Impact of the Type I Interferon Receptor on the Global Gene Expression Program During the Course of Dendritic Cell Maturation Induced by Polyinosinic Polycytidylic Acid.

Authors:  Amy L Olex; William H Turkett; Kristina L Brzoza-Lewis; Jacquelyn S Fetrow; Elizabeth M Hiltbold
Journal:  J Interferon Cytokine Res       Date:  2016-04-01       Impact factor: 2.607

Review 9.  Myeloid cells - targets of medication in multiple sclerosis.

Authors:  Manoj K Mishra; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2016-08-12       Impact factor: 42.937

Review 10.  Regulation of human glia by multiple sclerosis disease modifying therapies.

Authors:  Luke M Healy; Mackenzie A Michell-Robinson; Jack P Antel
Journal:  Semin Immunopathol       Date:  2015-08-11       Impact factor: 9.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.